Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults
Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults
复制标题
DOI：
10.1007/s11060-008-9617-2
复制
发表时间：
2008-09-01
影响因子：
3.9
通讯作者：
Olson, Jeffrey J.
中科院分区：
文献类型：
--
作者：
Buatti, John;Ryken, Timothy C.;Olson, Jeffrey J.
虽然放射治疗已经成为恶性胶质瘤治疗的标准疗法超过25年，但关于提供这种治疗的最佳方式仍然存在争议。由于20世纪70年代末和80年代初的几项随机试验显示放射治疗的益处，沿着的回顾性研究显示局部复发率很高，因此确定了剂量递增的研究阶段。评价了常规、超分割、加速和低分割放疗的剂量递增。还评价了增加的局部剂量，包括立体定向放射外科手术和近距离放射治疗。通常，生存期已被用作临床试验的终点，但对生活质量问题的日益关注已产生了更多信息，特别是在老年患者和预后不良组中。
Although radiation therapy has been a standard therapy for the treatment of malignant glioma for more than 25 years there remains controversy as to the optimal way to deliver this therapy. Because of several randomized trials in the late 1970s and early 1980s that showed a benefit with radiation treatment along with retrospective series showing that there was a high rate of local recurrence; the stage was set for dose escalation to be studied. Dose escalation in conventional, hyper-fractionated, accelerated and hypo-fractionated radiotherapy was evaluated. Increased local dose was also evaluated including stereotactic radiosurgery and brachytherapy. Generally survival has been used as the endpoint for clinical trials, but increasing interest in quality of life issues has yielded additional information particularly in the older patients and poor prognostic groups.